ijms-logo

Journal Browser

Journal Browser

Molecular Mechanisms and Therapies of Hematological Tumors

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: 20 July 2025 | Viewed by 908

Special Issue Editors


E-Mail Website
Guest Editor
IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, FC, Italy
Interests: leukemia; diagnostic; MPN; NGS

E-Mail Website
Guest Editor
IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, FC, Italy
Interests: acute myeloid leukemia; genomics; cell metabolism; targeted therapies
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Hematological malignancies consist of different cancers including leukemias, lymphomas, multiple myeloma, myeloproliferative neoplasms, and myelodysplastic syndromes. Recent advances in sequencing technologies have better defined the genomic landscape of hematological diseases and partially explained the molecular mechanisms underlying the carcinogenesis processes. This led to the development of different target therapies such as IDH inhibitors or BCL2 inhibitors that can be used beyond the standard chemotherapy to target and resolve the complexity of hematological disease and improve patient outcomes. Recently, the pathogenic roles of KMT2A rearrangements have been elucidated and patients characterized by this structural alteration can take advantage from Menin inhibitor use. Despite this, leukemic stem cells possess different relapse/refractory mechanisms, for example, multi-drug resistance, responsible for the relapse of disease.

This Special Issue aims to explain new insights into genetic and epigenetic alterations, cancer metabolism, target therapies, therapy response, drug resistance and relapse of the disease. Both original research articles, including in vitro studies, and reviews articles are strongly invited for submission.

Dr. Maria Teresa Bochicchio
Dr. Giorgia Simonetti
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • genetic alterations
  • next-generation sequencing
  • molecular biomarkers
  • target therapy
  • drug resistance

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

26 pages, 1955 KiB  
Review
From Chemotherapy to Targeted Therapy: Unraveling Resistance in Acute Myeloid Leukemia Through Genetic and Non-Genetic Insights
by Shuting Cao, Qiuxia Wang and Ganqian Zhu
Int. J. Mol. Sci. 2025, 26(9), 4005; https://doi.org/10.3390/ijms26094005 - 24 Apr 2025
Viewed by 397
Abstract
Acute myeloid leukemia (AML) is a devastating disease characterized by extensive inter-patient and intra-patient heterogeneity. Despite the introduction of intensive chemotherapy in the 1970s as the standard treatment, the development of mechanism-based targeted therapies since 2017 has been broadening the therapeutic landscape. However, [...] Read more.
Acute myeloid leukemia (AML) is a devastating disease characterized by extensive inter-patient and intra-patient heterogeneity. Despite the introduction of intensive chemotherapy in the 1970s as the standard treatment, the development of mechanism-based targeted therapies since 2017 has been broadening the therapeutic landscape. However, both chemotherapy and targeted therapies continue to face the challenges of primary and secondary resistance. This review summarizes the mechanisms underlying resistance to chemotherapy and targeted therapies in AML and discusses the opportunities and challenges brought by the transition from chemotherapy to precision medicine. Full article
(This article belongs to the Special Issue Molecular Mechanisms and Therapies of Hematological Tumors)
Show Figures

Figure 1

Back to TopTop